|
Comorbidity
|
Tamoxifen user vs. non-user HR (95 % CI)
|
p-value
|
Interaction p
|
|---|
|
Hypertension
| | |
0.18
|
|
No
|
0.67 (0.53-0.85)
|
0.001
| |
|
Yes
|
0.55 (0.46-0.66)
|
<0.0001
| |
|
Hyperlipidemia
| | |
0.97
|
|
No
|
0.60 (0.50-0.72)
|
<0.0001
| |
|
Yes
|
0.58 (0.45-0.74)
|
<0.0001
| |
|
Diabetes
| | |
0.56
|
|
No
|
0.62 (0.52-0.74)
|
<0.0001
| |
|
Yes
|
0.54 (0.41-0.71)
|
<0.0001
| |
|
PAD
| | |
0.58
|
|
No
|
0.59 (0.50-0.68)
|
<0.0001
| |
|
Yes
|
0.73 (0.37-1.46)
|
0.38
| |
|
Stroke
| | |
0.32
|
|
No
|
0.59 (0.50-0.69)
|
<0.0001
| |
|
Yes
|
0.68 (0.41-1.13)
|
0.14
| |
|
Osteoporosis
| | |
0.33
|
|
No
|
0.61 (0.51-0.73)
|
<0.0001
| |
|
Yes
|
0.54 (0.40-0.72)
|
<0.0001
| |
- PAD, peripheral artery disease
- Manually adjusted for monthly income, comorbidity and aromatase inhibitor use before the end point
